Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: A Pilot Phase I/II Feasibility Study | Zendy

Zakaria Einbeigi | Zendy; Daniel Bergström | Zendy; Thomas Hatschek | Zendy; Martin Malmberg | Zendy

Open Access

Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: A Pilot Phase I/II Feasibility Study

Author(s) -

Zakaria Einbeigi,

Daniel Bergström,

Thomas Hatschek,

Martin Malmberg

Publication year - 2008

Publication title -

clinical medicine oncology

Language(s) - English

Resource type - Journals

ISSN - 1177-9314

DOI - 10.4137/cmo.s1027

Subject(s) - capecitabine , epirubicin , medicine , metastatic breast cancer , paclitaxel , oncology , breast cancer , chemotherapy , cancer , phases of clinical research , surgery , urology , colorectal cancer

Thirteen patients with untreated metastatic breast cancer received epirubicin 60 mg/m(2), paclitaxel 155 mg/m(2) (both day 1) and capecitabine 665 mg/m(2) twice daily (days 1-14) every 21 days, with intra-patient dose escalation/reduction. Grade 3/4 events were infrequent. Nine patients (69%) achieved an objective response. Median time to progression and overall survival were 6.6 and 23.5 months, respectively.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research